Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.

NCT07491042 | Recruiting

• 1 other identifier: 67663
• Study Type: interventional
• Target: 38
• Locations: 1 country
• Sites: 1

Brief Summary

This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis. Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laboratory parameters will be assessed at baseline, then three and six months after drug initiation. The primary outcomes are:1- change in ultrafiltration volume, 2- change in Kt/V (dialysis adequacy), 3. Change in the mean 24-hour urine volume.

Conditions

End Stage Chronic Renal Failure

Keywords

SGLT-2 inhibitor; Peritoneal Dialysis; urine volume

Outcome Measures

Primary Outcomes (1)

• change in ultrafiltration volume in liter

  Dapagliflozin improves the Ultrafiltration in patients on PD

  3 months

Secondary Outcomes (1)

• Follow-up of the blood glucose in millimole/L.

  3 months

Study Arms (1)

selective SGLT2i Dapagliflozin and peritoneal dialysis

EXPERIMENTAL

it is clinical trial on drug Dapagliflozin and its effect on peritoneal dialysis: UF, Kt/V, and residual renal function, No of patients is 38

Drug: Dapagliflozin

Interventions

Dapagliflozin DRUG

study the effect of selective SGLT2i Dapagliflozin on peritoneal dialysis patients regarding UF/Kt/v and residual renal function

Also known as: SGLT2i

selective SGLT2i Dapagliflozin and peritoneal dialysis

Eligibility Criteria

• Age: 13 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• o age equal to or more than13 years.
• All genders.
• All patients undergoing chronic Peritoneal Dialysis.
• Urine output equal or more than 150 ml/24 hours.

You may not qualify if:

• o Age less than 13 years
• Patients with type I diabetes mellitus.
• Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D).
• Patients with urine output less than 150 ml/24hours.
• Patients with recurrent hypoglycemic episodes
• Patients with acute or chronic liver disease,
• Patients who refuse to participate in the study.
• peritoneal Dialysis catheter (PDC) related peritonitis in last 3 months

Sponsors & Collaborators

• Oman Ministry of Health: lead

Study Sites (1)

Jehad Badawi AL LAHAM

Nizwá, Oman

RECRUITING

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

dapagliflozin

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Jehad Badawi B AL LAHAM

CONTACT

94478719; sarkosyr@gmail.com

Jehad Badawi B AL LAHAM

CONTACT

94478719; jehad.laham@outlook.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: March 12, 2026
• First Posted: March 24, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): January 31, 2027
• Last Updated: March 24, 2026

Record last verified: 2026-03

Locations

OM (1)